UNSPSC 51172316: Dimercaptosuccinic acid or succimer

This classification denotes a metal chelator with the molecular formula C4H6O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DX1U2629QE, chemically known as 2,3-dithio-meso-tartaric acid but generally known as succimer, which bears US NIH Compound Identifier 9354. European Medicines Agency schedules Succimer in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10663MIG.

The term SUCCIMER is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). SUCCIMER is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Dimercaptosuccinic acid or succimer bears US NLM identifiers UMLS ID C0012384 and NCI Concept Code C61953. SMILES: C(C(C(=O)O)S)(C(=O)O)S.

UNSPSC 51172316 Dimercaptosuccinic acid or succimer is a Commodity code for pharmaceutical active pharmaceutical ingredients, but the recent state and local procurement activity recorded under it does not align with the code's nominal scope. The single recent opportunity—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—concerns laboratory testing operations, staffing, and result reporting rather than procurement of the chemical compound itself. The scope includes immunoassay screening with LC/MS/MS or GC/MS confirmation, operation of an Interactive Voice Response system for randomized testing notifications, electronic result reporting, and alternative testing methodologies including oral fluid and hair analysis, with no reference to dimercaptosuccinic acid or related toxicology products. This mismatch suggests the code may be misapplied in the source system or the opportunity was tagged incorrectly.

Collin County, Texas, posted RFP 2026-327 on September 25, 2026, with proposals due July 23, 2026, for a two-year contract term commencing September 1, 2026, at an estimated value of $600,000, with three optional one-year renewals. The solicitation permits award to multiple vendors and requires lab certification from SAMHSA, TX DPS, or CAP. Pricing is submitted on a per-test basis across three service models—screening only, confirmation after screening, and screening with automatic confirmation of positives—with annual testing demand of approximately 25,031 tests. The code shows little relevant recent activity aligned with its pharmaceutical-ingredient classification, and no additional state or local opportunities under this code are present in the source.